Literature DB >> 18655016

The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment.

Robert M Califf1, Judith M Kramer.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18655016     DOI： 10.1002/pds.1617

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN： 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  1 in total

1.  Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.

Authors:  Joshua D Wallach; Kun Wang; Audrey D Zhang; Deanna Cheng; Holly K Grossetta Nardini; Haiqun Lin; Michael B Bracken; Mayur Desai; Harlan M Krumholz; Joseph S Ross
Journal:  BMJ       Date:  2020-02-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.